ACW secures funding beyond XanaMIA AD trial final results
Key points
- Actinogen raises ~$12M via share placement, CEO/directors participate
- Funds to complete XanaMIA trial, open-label extension, and general purposes
- Eligible shareholders can participate in up to $5M share purchase plan
Full summary
Actinogen Medical has received firm commitments for a $12 million share placement to sophisticated and professional investors, including participation from the CEO and directors. The funds will be used to complete the XanaMIA pivotal trial in Alzheimer's disease, implement the open-label extension phase of the XanaMIA trial, and for general corporate purposes. The placement represents a material de-risking event for the XanaMIA phase 2b/3 AD trial, which is progressing towards completion and final topline results in November 2026. Actinogen will also undertake a share purchase plan of up to $5 million to provide eligible shareholders the opportunity to participate on the same terms as the placement. The company's lead compound, Xanamem, is being developed as a novel therapy for Alzheimer's disease and other neurological conditions by controlling elevated levels of cortisol in the brain.
Guidance
The company has not provided any high-importance, price-sensitive forward-looking financial metrics in the announcement.
Outlook
The company has not provided any forward-looking outlook statements in the announcement.
Summary generated by a large language model. Please interpret with care.